The European e-health opportunity: A context for pharmaceutical marketing

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 1, Issue 4, 2001, Pages 326-339

  Lerer, Leonard ^a  

^a NONE

Author keywords

direct to consumer advertising; e health; Europe; health consumer; health systems; Internet; pharmaceutical marketing; portals

Indexed keywords

EID: 84990361385     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040044     Document Type: Article

References (38)

1. Shaffer R. (1999) ‘ The Internet may finally cure what ails America's health care system’, Fortune, 105.
2. Goldstein D. (2000) e-Healthcare: Harness the Power of Internet e-Commerce and e-Care. Gaithersburg, Maryland, Aspen Publishers.
3. US Internet Council (2000) State of the Internet. ITTA for the US Internet Council.
4. Bickert M. (1999) The impact of Ecommerce on legacy health-care companies. New York, Cyber Dialogue.
5. Law J. (2000) ‘Pharma's strategy e-volves’, Scrip, December, 6–9.
6. Cjorstens M. Carpenter M. (2000) ‘ From Managing Pills to Managing Brands’, Harvard Business Review, March-April, 20–22.
7. First Consulting Group (1999) Where will the Road to E-Health Lead? — ‘Ten E-Health Trends’.
8. Waldholz M. Moore S. (2000) ‘ Glaxo, SmithKline vow to outrun rivals’, Wall Street Journal Europe, 18 January.
9. Jupiter Communications (2000) Pharmaceutical Marketing Online — Future blockbuster communication strategies require up-front R&D. New York, Jupiter Communications.
10. KPMG and The Economist Intelligence Unit (2000) The e-business value chain: Winning strategies in 7 industries. London, KPMG and The Economist Intelligence Unit.
11. Beynon K. (2000) ‘ Pharma lags behind in the e-environment’, Scrip, February, 54–56.
12. Kleinke J. (2000) ‘ Vaporware.com: The failed promise of the health care Internet, why the Internet will be the next thing not to fix the US health care system’, Health Affairs 19, 57–71.
13. Connectis (2001) Financial Times, March 14.
14. Eysenbach G. Sa E. R. Diepgen T. L. (1999) ‘ Shopping around the internet today and tomorrow: Towards the millennium of cybermedicine’, British Medical Journal 319(7220), 1294.
15. Goldstein D. British Medical Journal.
16. Economist (1999) ‘ A dose of reality’, The Economist, December 1, 60–61.
17. Anderson G. F. Poullier J. P. (1999) ‘ Health spending, access and outcomes: Trends in industrialised countries’, Health Affairs 18(3), 178–192.
18. Shaffer R. Health Affairs.
19. MerckMedco website. http://www.merckmedco.com (last accessed March 12, 2000).
20. Rowin Group, ‘Consumers rate Prevacid, Zocor and Nolvadex as top three Web sites. http://www.eyeforpharma.com (last accessed March 16, 2000).
21. Eysenbach G. Diepgen T. L. (1998) ‘ Towards quality management of medical information on the internet: Evaluation, labelling, and filtering of information’, British Medical Journal 317(7171), 1496–1500.
22. Eysenbach G. (2000) ‘Introduction into the MedCERTAIN trustmark concept and the need for international collaboration’, Journal of Medical Internet Research 2(suppl 2), e3.
23. Le Quotidien du Médecin (1999) ‘ Fin de la première tranche de réévaluation des médicaments’, Le Quotidien du Médecin, 2.
24. Price D. Pollock A. M. Shaoul J. (1999) ‘ How the World Trade Organization is shaping domestic policies in health care’, Lancet 354, 1889–1892.
25. Iglehart J. K. (1999) The American health care system — expenditures’, New England Journal of Medicine 340(1), 70–76.
26. Anderson Poullier, New England Journal of Medicine.
27. Huttin C. (1999) ‘ Drug price divergence in Europe: Regulatory aspects’, Health Affairs 18(3), 245–249.
28. Danzon P. M. Chao L. W. (2000) ‘ Cross-national price differences for pharmaceuticals: How large and why?’, Journal of Health Economics 19, 159–195.
29. Pilling D. (1998) ‘ Drug groups set to boost patient helplines’, Financial Times, October 19.
30. Neves A. (2001) ‘ DTC advertising: How to be innovative and produce DTC added value campaigns in the European regulatory environment’, in E-Business for European Pharmaceuticals Summit 2001, London: IQPC.
31. Scrip, (1999) ‘French pharmaceutical distribution costs “too high”’, 2483 22 October, 6.
32. Donelan K., et al(1999) ‘ The cost of health system change: Public discontent in five nations’, Health Affairs 18(3), 206–216.
33. Goldsbrough P. Lawyer P. (1999) The pharmaceutical industry into its second century: From serendipity to strategy. New York, The Boston Consulting Group.
34. Andersen Consulting (1997) ‘The globalization of managed care’ in Health Futures Forum. Singapore, Andersen Consulting.
35. Saltman R. B. Figueras J. (1998) ‘ Analyzing the evidence on European health care reforms’, Health Affairs 17(2), 85–108.
36. Wilson S. (1999) ‘ Impact of the internet on primary care staff in Glasgow’, Journal of Medical Internet Research 1(2), e7.
37. Lerer L. Rowell N. (2000) ‘INSEAD on the e-health consumer’, Fontainebleau, INSEAD.
38. Henke K. Hofman A. Hoppe J. Schroeder J. Wandschneider U. (2000) (eds.) Innovatives Gesunheitsmanagement im Zeichen Europas, Munich, Prokon Verlag.